샘플 요청 목록

 카트 문의
시장보고서
상품코드
1742795

혈장 유래 의약품 시장

Plasma-Derived Medicines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 391 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 혈장 유래 의약품 시장은 2030년까지 251억 달러에 달할 전망

2024년에 179억 달러로 추정되는 세계의 혈장 유래 의약품 시장은 2024-2030년의 분석 기간에 CAGR 5.7%로 성장하며, 2030년에는 251억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 면역글로불린은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 97억 달러에 달할 것으로 예상됩니다. 응고인자 부문의 성장률은 분석 기간 중 CAGR 7.1%로 추정됩니다.

미국 시장은 49억 달러로 추정, 중국은 CAGR 8.8%로 성장 예측

미국의 혈장 유래 의약품 시장은 2024년에 49억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 8.8%로 추이하며, 2030년까지 50억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.9%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 혈장 유래 의약품 시장 - 주요 동향과 촉진요인 정리

혈장 유래 의약품이 희귀질환 및 만성질환 치료에 필수적인 이유는?

제공된 인간 혈장을 분획하여 얻은 혈장 유래 의약품은 혈우병, 원발성 면역결핍증, 유전성 혈관부종, 자가면역질환 등 생명을 위협하는 다양한 만성질환의 치료에 중요한 역할을 하고 있습니다. 이러한 생물제제에는 면역글로불린(IVIG/SCIG), 응고인자(혈액응고인자 VIII, 혈액응고인자 IX), 알부민, 노출 후 예방에 사용되는 고면역글로불린 등이 포함됩니다. 합성 의약품과 달리 혈장 유래 요법은 저분자 대체품으로 대체할 수 없는 복잡한 생물제제이며, 많은 경우 환자에게 유일한 치료 옵션으로 남아 있습니다.

면역결핍증과 희귀 출혈성 질환이 전 세계에서 확산됨에 따라 그 중요성이 더욱 커지고 있습니다. 특히 진단 능력이 확대되고 신생아 선별 검사 프로그램을 통해 환자들이 조기에 발견될 수 있게된 것이 가장 큰 이유입니다. 또한 혈장 기반 치료법은 패혈증성 쇼크, 길랑-바레 증후군, 이식 후 면역 조절 등 적응증 외 치료 및 중환자 치료의 영역에서 점점 더 많이 사용되고 있습니다. 전 세계에서 만성 면역 질환을 앓고 오래 사는 인구가 증가함에 따라 혈장 단백질에 대한 의료 의존도는 계속 증가하고 있으며, 수요 및 공급망 모두에 상승 압력을 가하고 있습니다.

공급망을 형성하는 기술적, 경영적 과제는?

혈장 유래 의약품의 제조는 엄격한 기증자 선별, 혈장 채취, 병원체 비활성화, 콜드체인 물류 등 고도로 전문적이고 자원 집약적인 과정입니다. 혈장 단백질을 분리하는 과정인 분획은 여러 정제 및 검증 과정을 거치기 때문에 채취부터 최종 제품까지 7-12개월이 소요됩니다. 이러한 긴 리드타임과 엄격한 생물학적 표준 및 배치 변동성이 결합되어 이 산업은 매우 자본 집약적이고 컴플라이언스 중심적인 산업입니다. COVID-19 팬데믹으로 인해 전 세계에서 혈장 제공이 크게 감소한 것처럼, 기증자 확보와 시설 운영에 차질이 생기면 다운스트림 공급 병목 현상이 발생할 수 있습니다.

크로마토그래피, 바이러스 여과, 나노 여과 기술의 발전으로 혈장 유도체의 수율, 순도, 안전성이 향상되고 있습니다. 자동화된 플라즈마 페레시스 시스템과 디지털 기증자 참여 툴은 수집 효율을 높이고 있습니다. 그러나 이러한 발전의 확장성은 혈장의 생물학적 특성에 의해 제약을 받습니다. 또한 병원체 안전은 여전히 최우선 과제이며, 규제상의 의무로 인해 용매-세제 처리 및 가열 저온 살균과 같은 여러 바이러스 비활성화 공정이 필요하며, 이는 모든 제품에 비용과 복잡성을 추가합니다. 이러한 현실은 세계 혈장 공급의 불균형을 초래하고, 신흥 시장은 특히 미국의 소수의 대규모 기증자 네트워크에 크게 의존하고 있습니다.

세계 시장 리더와 정부는 증가하는 수요에 어떻게 대응하고 있는가?

증가하는 수요에 대응하기 위해 바이오 제약사들은 혈장 채취 센터 확장, 분획 능력 업그레이드, 제조 지역화에 많은 투자를 하고 있으며, CSL 베링거인겔하임, 글리볼렉스, 다케다제약, 옥타파마 등 업계 선두주자들은 독립적인 수집 네트워크를 인수하고, 혈장은행을 구축하고, 기증자 지원 활동을 디지털 건강 플랫폼과 통합하고 있습니다. 이들 기업은 또한 동남아시아, 라틴아메리카, 동유럽 등 혈장 접근성이 부족한 지역에서 혈장 접근성을 개선하기 위해 민관 파트너십을 형성하고 있습니다.

각국 정부와 규제기관은 국내 혈장 공급의 안전성을 보호하기 위한 조치를 취하고 있습니다. 유럽연합 집행위원회의 혈액 및 혈장 구상(Blood and Plasma Initiative)와 미국 HHS가 지원하는 혈장 단백질 치료 협회(PPTA)와 같은 구상은 자발적 헌혈을 장려하고, 상환 모델을 개선하며, 지역 수집 인프라에 인센티브를 제공합니다. 세계보건기구(WHO)는 특히 중저소득 국가에서 자급자족 전략을 개발할 것을 촉구하고 있으며, 수입품에 대한 의존도는 환자들을 결핍과 가격 충격에 취약하게 만듭니다. 한편, 신흥 생명공학 기업은 인간 혈장에 대한 의존도를 낮추기 위해 유전자 재조합 대체품이나 합성생물학적 접근법을 모색하고 있지만, 아직은 초기 임상 단계에 머물러 있습니다.

혈장 유래 의약품 시장의 장기적인 성장 동력은?

세계 혈장 유래 의약품 시장의 성장은 면역 결핍 및 희귀 혈액 질환의 유병률 증가, 세계 진단 능력의 향상, 적응증 외 적용 확대 등 여러 요인에 의해 이루어지고 있습니다. 신경학 및 자가면역 치료에서 IVIG의 사용 증가, 간 질환 및 중환자 치료에서 알부민에 대한 수요 증가로 인해 시장은 전통적인 혈액학 기반을 넘어 확장되고 있습니다. 또한 특히 선진국에서는 인구 고령화가 진행되고 있으며, 고령 환자들은 노화에 따른 면역력 저하로 면역글로불린 요법을 필요로 하므로 치료량 증가에 기여하고 있습니다.

또한 혈장 안전에 대한 규제 당국의 강력한 지원, 헌혈에 대한 대중의 인식 제고, 주요 바이오 제약사의 전략적 투자로 인해 공급망이 강화되고 있습니다. 위탁 혈장 분획 서비스, 디지털 기증자 참여 툴, 맞춤형 치료 요법의 성장으로 더 나은 생산 계획과 치료 맞춤화가 가능해졌습니다. 또한 신흥 국가들의 혈장 수집 및 제조 분야 진출로 인해 세계 접근성이 향상되고 지역 간 격차가 줄어들 것으로 예측됩니다. 만성질환 관리가 생물제제 중심으로 바뀌고 전 세계 의료 시스템이 희귀질환 치료의 지속성을 우선시함에 따라 혈장 유래 의약품은 향후 수년간 강력하고 지속적인 성장을 이룰 준비가 되어 있습니다.

부문

제품(면역글로불린, 응고인자, 알부민, 기타 제품), 유통 채널(병원 약국, 소매 약국, 온라인 약국), 용도(골반 내염증성 질환, 출혈성 질환,α1 항트립신 결핍증, 유전성 혈관부종, 만성 염증성 탈수초성 다발신경염, 길랭-바레 증후군, 다초점성 운동신경병증, 간질환, 원발성 면역성 혈소판 감소증, 기타 용도)

조사 대상 기업의 예(총 34건)

  • ADMA Biologics, Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Ltd(BPL)
  • Biotest AG
  • CSL Behring
  • China Biologic Products Holdings, Inc.
  • Fusion Healthcare
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Panacea Biotec
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • SK Plasma
  • Takeda Pharmaceutical Company Limited

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량경제 상황에서 이 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.19

Global Plasma-Derived Medicines Market to Reach US$25.1 Billion by 2030

The global market for Plasma-Derived Medicines estimated at US$17.9 Billion in the year 2024, is expected to reach US$25.1 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Immunoglobulin, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Coagulation Factors segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.8% CAGR

The Plasma-Derived Medicines market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.0 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Plasma-Derived Medicines Market - Key Trends & Drivers Summarized

Why Are Plasma-Derived Medicines Critical in Treating Rare and Chronic Disorders?

Plasma-derived medicines, obtained through fractionation of donated human plasma, play a vital role in managing a range of life-threatening and chronic conditions, including hemophilia, primary immunodeficiencies, hereditary angioedema, and autoimmune disorders. These biologics include immunoglobulins (IVIG/SCIG), clotting factors (Factor VIII, Factor IX), albumin, and hyperimmune globulins used in post-exposure prophylaxis. Unlike synthetic drugs, plasma-derived therapies are complex biologics that cannot be replaced with small-molecule alternatives, and in many cases, they remain the only therapeutic option available for patients.

Their importance has grown with the increasing global prevalence of immunodeficiencies and rare bleeding disorders, particularly as diagnostic capabilities expand and newborn screening programs identify affected individuals earlier. Additionally, plasma-based therapies are being increasingly used in off-label and critical care settings, such as septic shock, Guillain-Barre syndrome, and post-transplant immunomodulation. With a growing global population living longer with chronic immune conditions, the medical reliance on plasma proteins continues to intensify, creating upward pressure on both demand and supply chains.

What Are the Technological and Operational Challenges Shaping the Supply Landscape?

The production of plasma-derived medicines is a highly specialized, resource-intensive process involving rigorous donor screening, plasma collection, pathogen inactivation, and cold-chain logistics. Fractionation, the process of separating plasma proteins, takes 7-12 months from collection to final product due to multiple purification and validation steps. This extended lead time, combined with strict biological standards and batch variability, makes the industry highly capital- and compliance-intensive. Any disruption in donor availability or facility operations can result in downstream supply bottlenecks, as witnessed during the COVID-19 pandemic when plasma donations declined significantly worldwide.

Technological advances in chromatography, virus filtration, and nanofiltration are improving the yield, purity, and safety of plasma derivatives. Automated plasmapheresis systems and digital donor engagement tools are enhancing collection efficiency. However, the scalability of these advancements is constrained by the biological nature of plasma-each batch is unique, and consistent manufacturing outcomes require continuous quality control. Moreover, pathogen safety remains a top priority; regulatory mandates necessitate multiple virus inactivation steps, including solvent-detergent treatment and heat pasteurization, which add cost and complexity to every product. These operational realities have led to a global plasma supply imbalance, with developed markets heavily reliant on a few large-scale donor networks, especially in the U.S.

How Are Market Leaders and Governments Responding to Rising Global Demand?

To address growing demand, biopharmaceutical companies are investing heavily in expanding plasma collection centers, upgrading fractionation capacities, and regionalizing manufacturing to ensure better access and supply resilience. Industry leaders such as CSL Behring, Grifols, Takeda, and Octapharma are acquiring independent collection networks, building plasma banks, and integrating donor outreach with digital health platforms. These companies are also forming public-private partnerships to improve plasma access in underrepresented geographies, such as Southeast Asia, Latin America, and Eastern Europe.

Governments and regulatory bodies are taking steps to safeguard national plasma supply security. Initiatives such as the European Commission’s Blood and Plasma Initiative and the U.S. HHS-supported Plasma Protein Therapeutics Association (PPTA) are encouraging voluntary donation, improving reimbursement models, and incentivizing local collection infrastructure. The World Health Organization has called for the development of national self-sufficiency strategies, particularly in low- and middle-income countries, where reliance on imported products leaves patients vulnerable to shortages and price shocks. Meanwhile, emerging biotech firms are exploring recombinant alternatives and synthetic biology approaches to reduce dependency on human plasma, although such products are still in early clinical phases.

What’s Powering the Long-Term Growth of the Plasma-Derived Medicines Market?

The growth in the global plasma-derived medicines market is driven by several factors, including rising prevalence of immunodeficiencies and rare hematological disorders, improved global diagnostic capabilities, and expanding off-label applications. The increasing use of IVIG in neurology and autoimmune therapies, alongside growing demand for albumin in liver disease and critical care, is significantly expanding the market beyond its traditional hematology base. Aging populations, particularly in developed countries, are also contributing to higher treatment volumes, as older patients require immunoglobulin therapies for age-associated immune decline.

Furthermore, strong regulatory support for plasma safety, increasing public awareness of donation, and strategic investments by major biopharma companies are reinforcing supply chains. Growth in contract plasma fractionation services, digital donor engagement tools, and personalized therapy regimens is enabling better production planning and treatment customization. Additionally, the entry of emerging economies into the plasma collection and manufacturing space is expected to improve global accessibility and reduce regional disparities. As chronic disease management becomes more biologics-centric, and as global health systems prioritize continuity of care in rare disorders, plasma-derived medicines are poised for robust, sustained growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Plasma-Derived Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Immunoglobulin, Coagulation Factors, Albumin, Other Products); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Pelvic Inflammatory Disease, Bleeding Disorders, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • ADMA Biologics, Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Ltd (BPL)
  • Biotest AG
  • CSL Behring
  • China Biologic Products Holdings, Inc.
  • Fusion Healthcare
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Panacea Biotec
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • SK Plasma
  • Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Plasma-Derived Medicines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Immunoglobulins and Coagulation Factors Drives Growth in Plasma-Derived Medicines
    • Expansion of Rare Disease Diagnosis and Management Throws the Spotlight on Plasma Therapies
    • Innovation in Fractionation and Purification Processes Enhances Yield and Product Safety
    • Growth in Hemophilia, Primary Immunodeficiency, and Autoimmune Indications Spurs Clinical Demand
    • Collaboration With Blood Banks and Plasma Collection Networks Strengthens Supply Chain Security
    • Increasing Use of Albumin in Surgical and Trauma Care Expands Application Base in Critical Care
    • Investment in Pathogen Inactivation and Virus Filtration Enhances Regulatory Compliance
    • Surge in Demand for Intravenous and Subcutaneous Immunoglobulin Drives Manufacturing Capacity Expansion
    • Focus on Global Collection Infrastructure and Donor Pool Diversification Improves Supply Resilience
    • Rising Pressure to Meet cGMP and Pharmacopoeia Standards Spurs Facility Modernization Across Regions
    • Participation in Public-Private Partnerships Enhances Access to Plasma-Derived Therapies in LMICs
    • Growth in Transplantation and Neurological Indications Expands Indirect Demand for Plasma Derivatives
    • Entry Into Recombinant-Paired Product Pipelines Enhances Multi-Modality Therapy Options
    • Increasing Interest in Hyperimmune Globulins and Pandemic Readiness Strategies Strengthens Niche Markets
    • Emphasis on Donor Recruitment, Retention, and Plasma Incentivization Supports Collection Scale-Up
    • Rising Regulatory Harmonization Among FDA, EMA, and WHO Accelerates Product Approvals and Global Reach
    • Development of Long-Acting and Ready-to-Use Formats Enhances Patient Convenience and Compliance
    • Growth in Patient Advocacy and Reimbursement Campaigns Strengthens Policy Support for Plasma Therapies
    • Differentiation Through Orphan Drug Designation and Expanded Indication Approvals Boosts Market Position
    • Global Shift Toward Self-Administration and Home Infusion Solutions Propels Device-Integrated Plasma Drug Delivery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Plasma-Derived Medicines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Plasma-Derived Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Alpha-1 Antitrypsin Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Alpha-1 Antitrypsin Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Guillain-Barre Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Guillain-Barre Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Guillain-Barre Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Multifocal Motor Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Multifocal Motor Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Multifocal Motor Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Primary Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Primary Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Primary Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Pelvic Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Pelvic Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Pelvic Inflammatory Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Bleeding Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Bleeding Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Bleeding Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Plasma-Derived Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Spain 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Russia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Russia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Plasma-Derived Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Australia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Australia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Australia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: India 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: India 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: India 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: South Korea 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: South Korea 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: South Korea 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Plasma-Derived Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Latin America 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Latin America 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Argentina 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Argentina 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Argentina 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Brazil 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Brazil 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Brazil 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Mexico 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Mexico 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Mexico 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Plasma-Derived Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Middle East 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Middle East 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Iran 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Iran 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Iran 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Israel 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Israel 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Israel 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: UAE 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: UAE 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: UAE 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Africa 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Africa 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Africa 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제